vs
Lakeside Holding Ltd（LSH）与RETRACTABLE TECHNOLOGIES INC（RVP）财务数据对比。点击上方公司名可切换其他公司
RETRACTABLE TECHNOLOGIES INC的季度营收约是Lakeside Holding Ltd的1.3倍（$9.4M vs $7.0M），Lakeside Holding Ltd净利率更高（-22.6% vs -24.9%，领先2.3%），Lakeside Holding Ltd同比增速更快（95.0% vs 4.0%）
莱克赛德出版社是位于美国芝加哥的出版品牌，由RR唐纳利公司运营。该社除了出版高品质书籍外，还承印邮购目录、电话号码簿、百科全书与广告宣传品，最为人熟知的是为芝加哥卡克斯顿俱乐部出版的高端版本，以及经典重印丛书《莱克赛德经典》。
Retractable Technologies Inc是一家专业医疗设备制造商，主打可回缩注射器、安全针头、静脉导管等一次性安全医疗产品，客户覆盖医疗机构、制药企业及公共卫生部门，产品可有效降低医护人员与患者的针刺伤害风险。
LSH vs RVP — 直观对比
营收规模更大
RVP
是对方的1.3倍
$7.0M
营收增速更快
LSH
高出91.0%
4.0%
净利率更高
LSH
高出2.3%
-24.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $7.0M | $9.4M |
| 净利润 | $-1.6M | $-2.3M |
| 毛利率 | 27.2% | -16.2% |
| 营业利润率 | -21.3% | -81.7% |
| 净利率 | -22.6% | -24.9% |
| 营收同比 | 95.0% | 4.0% |
| 净利润同比 | 18.7% | -162.3% |
| 每股收益（稀释后） | $-0.08 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LSHRVP
| Q4 25 | $7.0M | $9.4M | ||
| Q3 25 | $6.1M | $10.1M | ||
| Q2 25 | $6.3M | $10.4M | ||
| Q1 25 | $3.8M | $8.3M | ||
| Q4 24 | $3.6M | $9.1M | ||
| Q3 24 | $4.1M | $10.3M | ||
| Q2 24 | — | $6.0M | ||
| Q1 24 | — | $7.6M |
净利润LSHRVP
| Q4 25 | $-1.6M | $-2.3M | ||
| Q3 25 | $-1.4M | $371.0K | ||
| Q2 25 | $-893.1K | $-87.5K | ||
| Q1 25 | $-1.1M | $-10.5M | ||
| Q4 24 | $-1.9M | $3.8M | ||
| Q3 24 | $-1.3M | $-1.9M | ||
| Q2 24 | — | $-14.2M | ||
| Q1 24 | — | $429.4K |
毛利率LSHRVP
| Q4 25 | 27.2% | -16.2% | ||
| Q3 25 | 18.2% | 16.7% | ||
| Q2 25 | 26.7% | -1.0% | ||
| Q1 25 | 18.8% | -0.0% | ||
| Q4 24 | -1.2% | -27.5% | ||
| Q3 24 | 12.8% | -0.1% | ||
| Q2 24 | — | -7.0% | ||
| Q1 24 | — | 25.0% |
营业利润率LSHRVP
| Q4 25 | -21.3% | -81.7% | ||
| Q3 25 | -20.8% | -36.2% | ||
| Q2 25 | -8.9% | -49.1% | ||
| Q1 25 | -28.2% | -56.4% | ||
| Q4 24 | -55.6% | -79.6% | ||
| Q3 24 | -32.5% | -49.6% | ||
| Q2 24 | — | -95.6% | ||
| Q1 24 | — | -39.3% |
净利率LSHRVP
| Q4 25 | -22.6% | -24.9% | ||
| Q3 25 | -22.2% | 3.7% | ||
| Q2 25 | -14.2% | -0.8% | ||
| Q1 25 | -28.2% | -126.6% | ||
| Q4 24 | -54.1% | 41.6% | ||
| Q3 24 | -32.7% | -18.6% | ||
| Q2 24 | — | -234.9% | ||
| Q1 24 | — | 5.7% |
每股收益（稀释后）LSHRVP
| Q4 25 | $-0.08 | $-0.09 | ||
| Q3 25 | $-0.09 | $0.01 | ||
| Q2 25 | $-0.11 | $0.00 | ||
| Q1 25 | $-0.14 | $-0.35 | ||
| Q4 24 | $-0.26 | $0.14 | ||
| Q3 24 | $-0.18 | $-0.07 | ||
| Q2 24 | — | $-0.48 | ||
| Q1 24 | — | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6M | $2.6M |
| 总债务越低越好 | $2.4M | $895.6K |
| 股东权益账面价值 | $12.2M | $74.4M |
| 总资产 | $24.3M | $142.6M |
| 负债/权益比越低杠杆越低 | 0.20× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资LSHRVP
| Q4 25 | $1.6M | $2.6M | ||
| Q3 25 | $4.5M | $3.4M | ||
| Q2 25 | $5.0M | $3.0M | ||
| Q1 25 | $1.5M | $3.4M | ||
| Q4 24 | $1.1M | $4.2M | ||
| Q3 24 | $2.7M | $3.9M | ||
| Q2 24 | — | $6.9M | ||
| Q1 24 | — | $10.0M |
总债务LSHRVP
| Q4 25 | $2.4M | $895.6K | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $1.4M | — | ||
| Q1 25 | $774.2K | — | ||
| Q4 24 | $784.8K | $1.2M | ||
| Q3 24 | $589.9K | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益LSHRVP
| Q4 25 | $12.2M | $74.4M | ||
| Q3 25 | $7.0M | $76.8M | ||
| Q2 25 | $2.8M | $76.5M | ||
| Q1 25 | $749.8K | $76.6M | ||
| Q4 24 | $1.6M | $87.2M | ||
| Q3 24 | $3.6M | $83.5M | ||
| Q2 24 | — | $85.4M | ||
| Q1 24 | — | $99.7M |
总资产LSHRVP
| Q4 25 | $24.3M | $142.6M | ||
| Q3 25 | $18.6M | $146.4M | ||
| Q2 25 | $14.4M | $147.1M | ||
| Q1 25 | $9.9M | $149.3M | ||
| Q4 24 | $9.8M | $160.7M | ||
| Q3 24 | $10.8M | $157.8M | ||
| Q2 24 | — | $160.7M | ||
| Q1 24 | — | $176.0M |
负债/权益比LSHRVP
| Q4 25 | 0.20× | 0.01× | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | 1.03× | — | ||
| Q4 24 | 0.48× | 0.01× | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-453.5K | $-596.5K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流LSHRVP
| Q4 25 | $-453.5K | $-596.5K | ||
| Q3 25 | $-4.0M | $-1.3M | ||
| Q2 25 | $-483.7K | $-3.7M | ||
| Q1 25 | $-238.3K | $-1.5M | ||
| Q4 24 | $-530.2K | $-1.1M | ||
| Q3 24 | $-1.4M | $-5.7M | ||
| Q2 24 | — | $-2.7M | ||
| Q1 24 | — | $-2.0M |
自由现金流LSHRVP
| Q4 25 | — | — | ||
| Q3 25 | — | $-1.3M | ||
| Q2 25 | $-497.4K | $-4.1M | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | $-560.5K | $-1.4M | ||
| Q3 24 | $-1.4M | $-6.5M | ||
| Q2 24 | — | $-2.8M | ||
| Q1 24 | — | $-2.2M |
自由现金流率LSHRVP
| Q4 25 | — | — | ||
| Q3 25 | — | -13.4% | ||
| Q2 25 | -7.9% | -38.9% | ||
| Q1 25 | — | -18.8% | ||
| Q4 24 | -15.6% | -15.5% | ||
| Q3 24 | -34.5% | -63.0% | ||
| Q2 24 | — | -46.8% | ||
| Q1 24 | — | -29.6% |
资本支出强度LSHRVP
| Q4 25 | — | — | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | 0.2% | 3.2% | ||
| Q1 25 | 0.0% | 1.0% | ||
| Q4 24 | 0.8% | 3.3% | ||
| Q3 24 | 0.1% | 7.7% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | — | 3.0% |
现金转化率LSHRVP
| Q4 25 | — | — | ||
| Q3 25 | — | -3.39× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -0.29× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -4.71× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LSH
| Transferred Over Time | $4.6M | 65% |
| Distribution Of Pharmaceutical Products | $2.4M | 35% |
RVP
暂无分部数据
